Identification of the genetic variants involved in the development of severe adverse drug reactions in cancer patients treated with cisplatin

鉴定与接受顺铂治疗的癌症患者发生严重药物不良反应有关的遗传变异

• 批准号: 361734
• 负责人: Drogemoller Britt I
• 金额: $ 9.83万
• 依托单位: University of British Columbia
• 依托单位国家: 加拿大
• 项目类别: Fellowship Programs
• 财政年份: 2016
• 资助国家: 加拿大
• 起止时间: 2016-11-01 至 2019-11-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=361734&lang=en
• 关键词: Adverse Drug Reactions; Cisplatin; Nephrotoxicity; Pharmacogenomics

Drug treatments are essential for the survival of cancer patients. Unfortunately, medications needed for treatment can also cause permanent disabling side effects, severely impacting on the quality of life of patients already suffering the devastating con

药物治疗对癌症患者的生存至关重要。不幸的是，治疗所需的药物也可能导致永久性的致残副作用，严重影响已经遭受毁灭性疾病的患者的生活质量。